Posted on 1/23/18
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it intends to . . .
Posted on 1/23/18
Insmed Announces Proposed Public Offering of Convertible Senior Notes
BRIDGEWATER, N.J., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of $300 million aggregate principal . . .
Posted on 1/22/18
Group Health Cooperative Eau Claire Partners with Valera in Innovative Behavioral Health Management
Brooklyn-based behavioral health startup Valera Health and Group Health Cooperative of Eau Claire have announced a partnership that will enhance behavioral health care management services for . . .
Posted on 1/22/18
Pfizer: The Best Big Pharma Dividend Stock
Pfizer (PFE) has long been one of my favorite pharmaceutical stocks. The last 5 years haven't been the best given an aging portfolio, but performance appears . . .
Posted on 1/22/18
Will This Tiny Biotech Be Celgene's Next Takeover Target?
Rumors are swirling that Celgene Corp (NASDAQ:CELG) is considering a multibillion-dollar acquisition of Juno Therapeutics (NASDAQ:JUNO). That got me thinking: What other companies could be on . . .
Posted on 1/22/18
3 Biotech Stocks That Soared This Week: Are They Buys?
You know it's a good week when a stock in your portfolio soars 28%. Actually, good is probably an understatement. But that's exactly what three biotech . . .
Posted on 1/22/18
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Your time horizon makes a huge difference when choosing between which stocks to buy. For example, suppose it's January 2011, and you're trying to decide between . . .
Posted on 1/22/18
Quest Diagnostics Named One of 2018 "World's Most Admired Companies" by Fortune Magazine for Third Consecutive Year
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named one of the "World's Most Admired Companies" . . .
Posted on 1/19/18
What's Juno Therapeutics Worth to Celgene?
Celgene Corp. (NASDAQ:CELG) owns ex-U.S. rights to Juno Therapeutics' (NASDAQ:JUNO)lead drug, liso-cel (formerly JCAR017), and it owns nearly 10% of Juno Therapeutics' stock, yet that may . . .
Posted on 1/19/18
Healthcare: Is Celgene Going to Buy Juno Therapeutics?
Rumors are swirling that Celgene Corp. (NASDAQ:CELG) may pay billions of dollars to buy Juno Therapeutics (NASDAQ:JUNO) lock, stock, and barrel. Do these rumors make sense?In . . .
Posted on 1/19/18
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
RA'ANANA, Israel and NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in . . .
Posted on 1/18/18
Johnson & Johnson Aims to Start 2018 Healthy
Johnson & Johnson (NYSE:JNJ) had a strong 2017, with its stock posting a nearly 25% total return. Key moves like the acquisitions of Actelion and Abbott . . .
Posted on 1/18/18
What's Juno Therapeutics Worth to Celgene?
Celgene Corp. (NASDAQ:CELG) owns ex-U.S. rights to Juno Therapeutics' (NASDAQ:JUNO)lead drug, liso-cel (formerly JCAR017), and it owns nearly 10% of Juno Therapeutics' stock, yet that may . . .
Posted on 1/17/18
Johnson & Johnson Issues Statement on ZYTIGA Inter Partes Reviews
Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate):"We are disappointed in and strongly disagree with the . . .
Posted on 1/17/18
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it has acquired . . .
Posted on 1/17/18
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
RA’ANANA, Israel and NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in . . .
Posted on 1/16/18
5 Biotech Stocks That Could Be Bought Out in 2018
Biotechnology merger and acquisition activity could get a booster shot now that U.S. tax reform is cutting corporate tax rates and allowing companies to repatriate cash . . .
Posted on 1/12/18
Here's What Celgene's Management Just Said About Its Future
Celgene Corp. (NASDAQ:CELG) has been one of biotech's brightest stars over the past decade, but its shares lost some luster following third-quarter 2017 financial results that . . .
Posted on 1/12/18
PreveCeutical Medical Receives Coverage from Crystal Equity Research
NEW YORK, Jan. 11, 2018 (GLOBE NEWSWIRE) -- NetworkNewsWire announces that Crystal Equity Research has published an initial report on PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H). . . .
Posted on 1/11/18
Celgene Tries To Rejoin The Party
BackgroundCelgene (CELG) has rejoined the group of biotechs trading at the same price they first reached when ascending to new heights in 2014. At $105-106 as . . .
Posted on 1/11/18
Celgene: Parsing Through The $7 Billion Impact Acquisition
Celgene CEO Mark AllesPresident Trump's tax cuts were expected to usher in a round of share buybacks and acquisitions in the biotechnology space. Celgene (CELG) answered . . .
Posted on 1/11/18
Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ)
The last five years have been kind to nearly all investors. But health-focused companies like Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) have been particularly profitable . . .
Posted on 1/10/18
Braeburn Announces Completion of $110 Million Financing
Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that the Company has completed a $110 million mezzanine round of financing led by Wellington Capital Management. Other new investors . . .
Posted on 1/10/18
Celgene - Strong Portfolio Should Support Growing Earnings
Celgene (NASDAQ: CELG) is a more than $80 billion biotech company that hurt its investors in late October, after a difficult environment forced the company to . . .
Posted on 1/10/18
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
Pfizer's (NYSE:PFE) president of worldwide research and development, Mikael Dolsten, represented the giant drugmaker at the annual J. P. Morgan (NYSE:JPM) Healthcare Conference on Monday. Dolsten's . . .

